We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Adjuvant Tamoxifen Effective in Younger Breast Cancer Patients

Jun 1, 1998
Volume: 
7
Issue: 
6
  • Breast Cancer

OXFORD, UK--The latest 5-year metaanalysis by the Early Breast Cancer Clinical Trialists’ Collaborative Group suggests that up to 20,000 additional lives could be saved each year worldwide if physicians prescribed adjuvant tamoxifen (Nolvadex) to all early breast cancer patients who could benefit, including premenopausal women.

The metaanalysis included detailed information from 55 randomized trials conducted over the past 2 decades in more than a dozen countries, involving 30,000 women with early breast cancer, researchers from the Clinical Trial Service Unit (CTSU) at Oxford University said at a press briefing.

Within 10 years of surgery, about one-third had relapsed and died. Starting tamoxifen early and continuing it for about 5 years cut the recurrence rate in half, irrespective of the patient’s age, and improved long-term survival. Tamoxifen proved effective regardless of whether chemotherapy was also given (ie, it had an added effect) or whether the patient was node negative or node positive (The Lancet, May 15, 1998).

Fewer Young Women Get the Drug

Professor Richard Peto, co-director of the CTSU, said: "Starting tamoxifen immediately after breast cancer surgery prevented one in six women from relapsing and one in 12 from dying, irrespective of age. Tamoxifen for older women is already saving more lives than any other cancer drug. But most of the younger breast cancer patients who need tamoxifen aren’t yet getting it."

The researchers cited data from a worldwide survey of 841 leading breast cancer doctors. Almost all (99%) of the doctors in the survey said that they might use tamoxifen in a woman of about age 60 with node-positive early breast cancer, but only 54% said they would use it in a node-positive woman in her 40s. In patients with node-negative disease, the percentages dropped to 78% for older women and 33% for younger women.

When the relatively small increased risk of endometrial cancer and pulmonary embolism with tamoxifen use is taken into account, tamoxifen was shown to prevent about 30 times as many deaths as it causes. Dr. Rory Collins, CTSU co-director, said "The beneficial effects of tamoxifen far outweigh any adverse effects on survival."

Related Articles

  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms
  • COUNTERPOINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
  • POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.